HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed Pediatric Pontine Glioma
Conditions
Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma, Recurrent Pediatric Low Grade Glioma
Trial Timeline
Feb 1, 2009 → Nov 1, 2024
NCT ID
NCT01130077About HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC
HLA-A2 restricted glioma antigen peptides vaccine + Poly-ICLC is a phase 1 stage product being developed by Brain Biotech for Newly Diagnosed Pediatric Pontine Glioma. The current trial status is completed. This product is registered under clinical trial identifier NCT01130077. Target conditions include Newly Diagnosed Pediatric Pontine Glioma, Newly Diagnosed Pediatric High Grade Glioma, Recurrent Pediatric High Grade Glioma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01130077 | Phase 1 | Completed |
Competing Products
18 competing products in Newly Diagnosed Pediatric Pontine Glioma